Halda Therapeutics appointments CMO

US clinical-stage biotech Halda Therapeutics today announced that Dr Eyal Attar has joined the company as chief medical officer (CMO). Dr Attar brings to Halda over 25 years of biotechnology R&D and clinical trial experience in the advancement of novel therapeutics.

“Dr Attar is a seasoned biotechnology industry veteran, and we are thrilled for him join the Halda team at this exciting time,” said Christian Schade, president and chief executive of Halda Therapeutics, adding: “As Halda advances our novel small molecule RIPTAC modality in clinical studies, the breadth of Eyal’s clinical development and R&D strategy experience will be instrumental to achieving our ambitious development goals and future success.”

“Halda’s novel RIPTAC small molecule platform is a new and exciting modality in the treatment of patients with cancer and other serious diseases,” said Dr Attar. “I look forward to working with the outstanding team at Halda and with clinical partners to advance the current clinical study in prostate cancer, the future RIPTAC development program in breast cancer, in addition to advancing this modality to patients with a range of other serious diseases.”